J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270008320316v1
48/8/919    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Google Scholar
Right arrow Articles by Séchaud, R.
Right arrow Articles by Balez, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Séchaud, R.
Right arrow Articles by Balez, S.

PHARMACOKINETICS

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

Romain Séchaud, PhD, Anna Robeva, Rossella Belleli, MSc and Sebastien Balez, PharmD

From Novartis Pharma AG, Basel, Switzerland (Dr Séchaud, Ms Belleli); Novartis Pharmaceuticals, East Hanover, New Jersey (Ms Robeva); and Novartis Pharma SAS, Rueil Malmaison, France (Dr Balez).

Deferasirox is a novel iron chelator formulated as tablets for dispersion (suspension) for once-a-day oral administration. The current study evaluated the absolute bioavailability of a single 375-mg oral dose of deferasirox administered in the form of tablets compared with a 130-mg intravenous infusion of deferasirox. Since this was a first-in-man study using the deferasirox intravenous (IV) formulation, the safety and tolerability of the IV formulation was evaluated in a pilot phase with a lower dose (65 mg) in 3 subjects prior to the main phase. The main study phase consisted of 17 healthy male volunteers. Plasma concentrations of deferasirox were measured following each treatment, and pharmacokinetic parameters including absolute oral bioavailability were determined. Absolute oral bioavailability of the deferasirox tablets was 70% (90% confidence interval, 62%-80%). Deferasirox was characterized as having a low plasma clearance of 3.53 (± 0.87) L/h. A small volume of distribution of deferasirox at steady state (Vss) of 14.37 (±2.69 L) was determined, indicating a low tissue distribution.

Key Words: Iron overload • chelation • bioavailability • deferasirox • pharmacokinetics

Address for reprints: Dr Romain Séchaud, Novartis Pharma AG, Exploratory Development, WSJ-210.4.020, CH-4002 Basel, Switzerland.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology